AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04960813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playgroup
Description: Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions.
Study NCT05086458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
Study NCT04734379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Oral fasudil 180 mg/day
Study NCT04161118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL019
Description: IV Infusion
Study NCT06043414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: triclosan-coated barbed suture
Description: STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
Study NCT06043414 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: triclosan-coated non-barbed suture
Description: PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
Study NCT06043414 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-coated non-barbed suture
Description: PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
Study NCT05294640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Bacteriostatic Local Anesthetic Injection
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Study NCT05294640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Study NCT06056531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near infrared light imaging
Description: The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
Study NCT06056531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise with stress ball
Description: Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
Study NCT05084807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy
Description: * A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range.
Study NCT06346600 — intervention group
Intervention type: GENETIC
Intervention: SKG0106
Description: Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
Study NCT04916067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Implantation
Description: Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
Study NCT06565832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Minute Sit-to-Stand Test
Description: This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
Study NCT06565832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chester Step Test
Description: This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
Study NCT04903717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practice Alert
Description: Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
Study NCT06567535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation and endoscopy
Description: The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
Study NCT04348292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04348292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT04520594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 7.5 g resistant starch/m2 oral consumption
Study NCT04520594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral consumption of food-grade cornstarch
Study NCT05961319 — intervention group
Intervention type: DEVICE
Intervention: Smart-Home Monitoring
Description: During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study.
Study NCT05294640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eyelid Lesion Removal
Description: Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
Study NCT05294640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Lesion Removal
Description: Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
Study NCT06568900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cigarette smoking
Description: continue smoking usual brand of cigarette
Study NCT06568900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tobacco flavored and unflavored pouch
Description: provide tobacco flavored and unflavored options of nicotine pouch
Study NCT06568900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: unrestricted flavor options pouch
Description: provide unrestricted flavor options of nicotine pouch
Study NCT06542887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
Study NCT06542887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
Study NCT06542887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Seed Oil Cap/Tab
Description: Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
Study NCT04671303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets
Description: Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle.
Study NCT06390111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadofaragene firadenovec
Description: The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
Study NCT05553600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon BR
Description: Modified Regular Absorbency Tampons
Study NCT05553600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon CR
Description: Reference Regular Absorbency Tampons
Study NCT05553600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon BS
Description: Modified Super Absorbency Tampons
Study NCT05553600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tampon CS
Description: Reference Super Absorbency Tampons
Study NCT05229562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.
Study NCT06060405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
Study NCT06060405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
Study NCT06368128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Rock Climbing Exercise Training Program
Description: Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
Study NCT05913297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance
Description: Magnetic Resonance
Study NCT05913297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnographic evaluation
Description: Polysomnographic evaluation
Study NCT04892901 — intervention group
Intervention type: PROCEDURE
Intervention: c-ESPB
Description: In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
Study NCT04892901 — intervention group
Intervention type: PROCEDURE
Intervention: c-SAPB
Description: In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
Study NCT04892901 — intervention group
Intervention type: PROCEDURE
Intervention: ICNB
Description: In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump.
Study NCT04844424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Study NCT05902195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Resource Building and Inclusive Volunteering Intervention (PVI)
Description: PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
Study NCT05902195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
Study NCT06097052 — intervention group
Intervention type: DEVICE
Intervention: Hypotension Predictive Index
Description: Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
Study NCT06038877 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Individual semi-structured interviews
Study NCT06038877 — intervention group
Intervention type: OTHER
Intervention: Qualitative analysis
Description: Thematic analysis of the content of responses
Study NCT06534736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy and physical agents
Description: It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
Study NCT06534736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
Study NCT06534736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization Exercise
Description: Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
Study NCT06097039 — intervention group
Intervention type: DEVICE
Intervention: abdominal U/S
Description: A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
Study NCT06097039 — intervention group
Intervention type: DEVICE
Intervention: Fibroscan with Controlled Attenuated Parameter (CAP scan):
Description: Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m).
Study NCT05057767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam injection
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
Study NCT05057767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
Study NCT05548543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.
Study NCT05548543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.
Study NCT05548543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.
Study NCT06117566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, once a day
Study NCT06117566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks
Study NCT05658692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.